183 related articles for article (PubMed ID: 18047674)
21. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2014; 201():27-65. PubMed ID: 24756784
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J
Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966
[No Abstract] [Full Text] [Related]
27. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
28. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Bryant G
Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
[TBL] [Abstract][Full Text] [Related]
29. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G
Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362
[TBL] [Abstract][Full Text] [Related]
30. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib.
Shah NP
Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
[TBL] [Abstract][Full Text] [Related]
32. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib: a new step in molecular target therapy.
Olivieri A; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi42-6. PubMed ID: 17591830
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
36. Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Verstovsek S
Leuk Res; 2009 May; 33(5):617-23. PubMed ID: 19013641
[TBL] [Abstract][Full Text] [Related]
37. Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.
Silveira RA; Fachel AA; Moreira YB; De Souza CA; Costa FF; Verjovski-Almeida S; Pagnano KB
Hematology; 2014 Jan; 19(1):31-41. PubMed ID: 23676950
[TBL] [Abstract][Full Text] [Related]
38. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
[TBL] [Abstract][Full Text] [Related]
39. Treatment-free remission after stopping second-line dasatinib.
Ross DM
Lancet Haematol; 2015 Dec; 2(12):e506-7. PubMed ID: 26686401
[No Abstract] [Full Text] [Related]
40. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
